Literature DB >> 1385890

Aspects on diagnosis and treatment of the foregut carcinoid syndrome.

H Ahlman1, B Wängberg, O Nilsson, L Grimelius, G Granérus, I M Modlin, O Stenqvist, T Scherstén.   

Abstract

Eight patients with the foregut carcinoid syndrome (two gastric and six bronchial primary tumors) are reported. The patients presented with complex clinical symptoms including ectopic production of adrenocorticotrophic hormone and growth hormone-releasing factors. The most alarming symptoms were facial flush and edema, accompanied by severe bronchoconstriction, which easily was misinterpreted as asthmatic attacks. Conventional bronchodilatory drugs may be potentially dangerous in these patients, in whom combined blockade of histamine receptors and treatment with cortisone and octreotide are recommended. Owing to the patients' age and general condition individualized long-term therapy was instituted. Surgical therapy under optimal protection by drugs can be of substantial value also in patients with advanced disease. One patient with life-threatening hormonal symptoms underwent hyperthermic perfusion of the liver with cytotoxic drugs, resulting in good palliation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385890     DOI: 10.3109/00365529209000106

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

Authors:  Gregory Kaltsas; Martyn Caplin; Philippa Davies; Diego Ferone; Rocio Garcia-Carbonero; Simona Grozinsky-Glasberg; Dieter Hörsch; Eva Tiensuu Janson; Reza Kianmanesh; Beata Kos-Kudla; Marianne Pavel; Anja Rinke; Massimo Falconi; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2017-03-02       Impact factor: 4.914

2.  Observations on relationship between hypergastrinemia, multiple gastric carcinoids, and pancreatic mass.

Authors:  I M Modlin; C J Gilligan; G P Lawton; L H Tang; A B West; R Lindenberg
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

3.  Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours.

Authors:  Apostolos V Tsolakis; Lars Grimelius; Göran Granerus; Mats Stridsberg; Sture E Falkmer; Eva T Janson
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

Review 4.  [Therapy of carcinoids of the stomach].

Authors:  H D Becker; A Gabriel
Journal:  Langenbecks Arch Chir       Date:  1996

Review 5.  Carcinoid tumours.

Authors:  S Janmohamed; S R Bloom
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

6.  Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

Authors:  Daniel M Halperin; Chan Shen; Arvind Dasari; Ying Xu; Yiyi Chu; Shouhao Zhou; Ya-Chen Tina Shih; James C Yao
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

7.  In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.

Authors:  Aleksandra Syguła; Aleksandra Ledwon; Kornelia Hasse-Lazar; Beata Jurecka-Lubieniecka; Barbara Michalik; Ewa Paliczka-Cieślik; Marcin Zeman; Ewa Chmielik; Joanna Sczasny; Barbara Jarzab; Daria Handkiewicz-Junak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-03       Impact factor: 10.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.